Showing results (341-350 of 481) with videos related to

Sort By:
Pageof 49
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2019
Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology GroupJennifer L McNeer, Meenakshi Devidas, Yunfeng Dai, et al.
Clinical Nephrology|January 12, 2023
Impact of focal segmental glomerulosclerosis over the past decadeKeng Thye Woo, Choong Meng Chan, Marjorie Foo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2022
Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/KMT2A Rearrangements in a Modern Therapy Era: A Retrospective International StudyAndishe Attarbaschi, Anja Möricke, Christine J Harrison, et al.
The Journal of Clinical Investigation|October 23, 2025
T-cell acute lymphoblastic leukemia exploits a neural proinflammatory pathway to colonize the meningesNitesh D Sharma, Esra'a Keewan, Wojciech Ornatowski, et al.
Cancer Research|October 17, 2020
Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Its Role in Drug ResistanceShella Saint Fleur-Lominy, Nikki A Evensen, Teena Bhatla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2020
Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434Robert J Hayashi, Stuart S Winter, Kimberly P Dunsmore, et al.
Genes, Chromosomes & Cancer|December 8, 2007
SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patientsKenneth D Swanson, Jordan M Winter, Marcelo Reis, et al.
Clinical Pharmacology and Therapeutics|March 26, 2021
Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase HypersensitivityYiwei Liu, Wenjian Yang, Colton A Smith, et al.
Molecular Cancer Therapeutics|December 16, 2014
Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemiaSanti Suryani, Lauryn S Bracken, Richard C Harvey, et al.
Pageof 49